Mayo Clinic | Strategic Alliance Partners

January 22, 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

July 23, 2014

Sean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.

June 09, 2014

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

May 15, 2014

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

April 08, 2014

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.

March 31, 2014

The role of allogeneic transplant in the treatment of adult patients with acute lymphoblastic leukemia (ALL) is evolving as a result of new studies providing evidence of the efficacy of an improved chemotherapy regimen

March 27, 2014

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia

March 06, 2014

As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.

February 27, 2014

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

January 23, 2014

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

January 15, 2014

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

October 31, 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CellSearch CTC Test in breast cancer.

October 18, 2013

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

October 17, 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

September 20, 2013

Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in metastatic breast cancer treatment.

September 03, 2013

A multisite, randomized, double-blind trial evaluating the fatigue-ameliorating properties of American ginseng in cancer patients and recent survivors has found the herb to be helpful in reducing some aspects of CRF, with the benefit strongest among patients currently in treatment.

August 07, 2013

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

August 01, 2013

The results of the first prospective multicenter trial of cryoablation in lung cancer show that this emerging treatment may be a safe, effective, and minimally invasive method of helping a specific group of patients with advanced disease.

July 23, 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

May 08, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.